As is generally the case for many areas of the stock market, summer marks a pronounced slowdown in newsflow and stock action for the healthcare sector. Although these periods can be frustrating for investors and traders who crave action, the sluggish pace of trading can afford others an opportunity to get caught up on due diligence and begin establishing positions.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Two Significant Cancer Companies Heading in Opposite Directions
With little of note on the horizon on this weekend, a quick look back at last week seems in order as it was a notable week for at least two oncology-focused biotechnology companies.

Dendreon (Nasdaq:DNDN) reported yet another disappointing quarter; a quarter that saw not only a significant restructuring announcement, but also a sequential decline in sales of the controversial cancer vacine Provenge. Although lauded as a first-of-its-kind therapy, Provenge has simply not caught on with the oncology community - likely due to a combination of its unconventional nature and the lack of response seen in traditional indicators (Provenge doesn't appreciably shrink tumors or lower PSA levels). While management believes that its latest round of cuts will allow the company to break even at $100 million in quarterly sales, very competitive new drugs from Johnson & Johnson (NYSE:JNJ) and Medivation (Nasdaq:MDVN) may make even that level of revenue production difficult.

SEE: How To Choose A Healthcare Plan

Speaking of Medivation, the company announced last weak that the FDA has set a PDUFA date for its heralded prostate cancer drug enzalutamide. On or about November 22, investors will know whether the FDA has approved the drug for sale in the United States or whether Medivation (and partner Astellas) will have to submit additional data.

The K-V Story Ends with a Whimper
This past weekend also saw the likely end of former controversial specialty drug company K-V Pharmaceutical, as the company declared Chapter 11 bankruptcy.

SEE: An Overview Of Corporate Bankruptcy

K-V had largely bet the company's future on Makena - a drug designed to prevent premature births. The controversy came from the fact that K-V had conducted trials and sought approval for Makena as an orphan drug, but compounding pharmacies had been producing the treatment (legally) for patients for years. Whereas pharmacies were charging $300 or less for a course of treatment, K-V initially tried to price Makena at around $25,000 without offering any appreciable improvement in safety or efficacy (rather, just the consistency of a single manufactured product versus the potential variability from compounding pharmacies).

K-V tried to enlist the FDA to eliminate the cheaper competition and force compounding pharmacies to cease selling their cheaper generic alternative as part of the orphan drug designation, but widespread public outrage (including the involvement of Congress) and an unclear legal precedent ultimately led the FDA to back down. K-V tried to reprice the drug (cutting the price by more than half), but could not gain any headway.

SEE: 5 Things To Know About Managing Your Healthcare Deductible

The Bottom Line
The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit. The Health Care Select Sector SPDR (ARCA:XLV) is up around 9.3% year-to-date, slipping below the the 9.7% return of the S&P 500. The iShares Dow Jones US Pharmaceuticals ETF (ARCA:IHE) is up 12.6%, while the iShares Dow Jones US Medical Devices ETF (ARCA:IHI) is up 8.1%. The SPDR S&P Biotech ETF (ARCA:XBI) has risen more than 30% year-to-date.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Short S&P500

    Find out information about the ProShares UltraPro Short S&P 500 exchange-traded fund, and learn detailed analysis of its characteristics and suitability.
  2. Mutual Funds & ETFs

    ETF Analysis: SPDR Barclays Investment Grd Fl Rt

    Learn more about the SPDR Barclays Investment Grade Floating Rate Fund, which tracks an index of highly rated floating debt securities.
  3. Mutual Funds & ETFs

    ETF Analysis: ALPS Medical Breakthroughs

    Learn more about a unique and innovative exchange-traded fund (ETF) in the biotechnology industry: the ALPS Medical Breakthroughs Fund.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares US Healthcare

    Learn about the iShares U.S. Healthcare exchange-traded fund, which invests in a wide range of health care providers, hospitals and home care facilities.
  5. Mutual Funds & ETFs

    Top 5 Japan Mutual Funds

    Discover five of the most popular and best-performing mutual funds offering investors direct exposure to equities of Japanese companies.
  6. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Clinical Trials

    Learn more about the BioShares Biotechnology Clinical Trials Fund, a new and innovative fund focusing on breakthroughs in the health industry.
  7. Mutual Funds & ETFs

    ETF Analysis: First Trust NYSE Arca Biotech

    Learn more about the First Trust NYSE Arca Biotechnology Fund, a highly rated exchange-traded fund in the biotech space.
  8. Mutual Funds & ETFs

    ETF Analysis: PowerShares KBW Bank

    Consider an examination and analysis of the PowerShares KBW Bank Portfolio ETF, considered one of the primary financial sector ETFs.
  9. Chart Advisor

    3 Ways to Trade the Rising Volatility

    With volatility increasing in the markets, many are turning to these three volatility-capturing exchange-traded products.
  10. Mutual Funds & ETFs

    ETF Analysis: iShares US Basic Materials

    Learn about the iShares US Basic Materials exchange-traded fund, which invests in the equities of chemicals, metals and industrial gas companies.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Exchange-Traded Fund (ETF)

    A security that tracks an index, a commodity or a basket of assets ...
  3. Exchange-Traded Mutual Funds (ETMF)

    Investopedia explains the definition of exchange-traded mutual ...
  4. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  5. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  6. Lion economies

    A nickname given to Africa's growing economies.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>
  5. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!